VRTX vs INCY — Key Metrics

Metric VRTX (VERTEX PHARMACEUTICALS INC) INCY (INCYTE CORP)
Price536.45117.8
Market Cap136.01 Billion24.01 Billion
P/E (TTM)34.2356.36
P/B (Quarterly)6.4364.219
P/S (TTM)10.53.99
Net Profit Margin (TTM)30.76.7
Gross Margin (TTM)85.592.7
ROE (TTM)20.17.1
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

VERTEX PHARMACEUTICALS INC
vs
 
INCYTE CORP
 
VERTEX PHARMACEUTICALS INC
vs
 
INCYTE CORP
Performance Comparison
AI Model Recommendation
VRTX · VERTEX PHARMACEUTICALS INC

Outperform

42
UnderperformOutperform
INCY · INCYTE CORP

Greatly Outperform

84
UnderperformOutperform
Recommendation Summary

Stock VRTX is projected to outperform the market, stock INCY is projected to greatly outperform the market. Upfront Recommendation: INCY.

Financial Metrics
Prices delayed ~15 min
VRTX Metrics INCY
$536.45 Price $117.80
— Market Capitalization —
34.23 Price to Earnings Ratio 56.36
10.5 Price to Sales 3.99
42.47 Price to FCF Ratio 35.06
12.28 Price to Gross Profit 4.31
32.0 Price to R&D 6.99
11.64 Price to Current Assets 4.35

VRTX vs INCY at a glance

Vertex Pharmaceuticals INC (VRTX) and Incyte Corp (INCY) are both Biotechnology companies in the Healthcare sector. VRTX is the larger, at $136.0 billion in market value against $24.0 billion for INCY, about 5.7 times the size.

On trailing-twelve-month figures, VRTX trades at 34.2 times trailing earnings and INCY at 56.4; net profit margins are 30.7% and 6.7%.

The Upfront Investment model currently rates VRTX Outperform and INCY Greatly Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.